Rebecca F Gottesman1, Andrea L C Schneider2, Yun Zhou3, Josef Coresh4, Edward Green5, Naresh Gupta6, David S Knopman7, Akiva Mintz8, Arman Rahmim3, A Richey Sharrett4, Lynne E Wagenknecht9, Dean F Wong10, Thomas H Mosley11. 1. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 2. Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Radiology, Section of High Resolution Brain PET Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland. 4. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 5. Department of Radiology, University of Mississippi Medical Center, Jackson. 6. Hagerstown Imaging, Hagerstown, Maryland. 7. Department of Neurology, Mayo Clinic, Rochester, Minnesota. 8. Department of Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 9. Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. 10. Department of Radiology, Section of High Resolution Brain PET Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland9Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland10Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland11Department of Environmental Health Sciences, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 11. Department of Medicine, University of Mississippi Medical Center, Jackson.
Abstract
IMPORTANCE: Midlife vascular risk factors have been associated with late-life dementia. Whether these risk factors directly contribute to brain amyloid deposition is less well understood. OBJECTIVE: To determine if midlife vascular risk factors are associated with late-life brain amyloid deposition, measured using florbetapir positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study, a prospective cohort study among 346 participants without dementia in 3 US communities (Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi) who have been evaluated for vascular risk factors and markers since 1987-1989 with florbetapir PET scans in 2011-2013. Positron emission tomography image analysis was completed in 2015. EXPOSURES: Vascular risk factors at ARIC baseline (age 45-64 years; risk factors included body mass index ≥30, current smoking, hypertension, diabetes, and total cholesterol ≥200 mg/dL) were evaluated in multivariable models including age, sex, race, APOE genotype, and educational level. MAIN OUTCOMES AND MEASURES: Standardized uptake value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated. Elevated florbetapir (defined as a SUVR >1.2) was the dependent variable. RESULTS: Among 322 participants without dementia and with nonmissing midlife vascular risk factors at baseline (mean age, 52 years; 58% female; 43% black), the SUVR (elevated in 164 [50.9%] participants) was measured more than 20 years later (median follow-up, 23.5 years; interquartile range, 23.0-24.3 years) when participants were between 67 and 88 (mean, 76) years old. Elevated body mass index in midlife was associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65). At baseline, 65 participants had no vascular risk factors, 123 had 1, and 134 had 2 or more; a higher number of midlife risk factors was associated with elevated amyloid SUVR at follow-up (30.8% [n = 20], 50.4% [n = 62], and 61.2% [n = 82], respectively). In adjusted models, compared with 0 midlife vascular risk factors, the OR for elevated SUVR associated with 1 vascular risk factor was 1.88 (95% CI, 0.95-3.72) and for 2 or more vascular risk factors was 2.88 (95% CI, 1.46-5.69). No significant race × risk factor interactions were found. Late-life vascular risk factors were not associated with late-life brain amyloid deposition (for ≥2 late-life vascular risk factors vs 0: OR, 1.66; 95% CI, 0.75-3.69). CONCLUSIONS AND RELEVANCE: An increasing number of midlife vascular risk factors was significantly associated with elevated amyloid SUVR; this association was not significant for late-life risk factors. These findings are consistent with a role of vascular disease in the development of Alzheimer disease.
IMPORTANCE: Midlife vascular risk factors have been associated with late-life dementia. Whether these risk factors directly contribute to brain amyloid deposition is less well understood. OBJECTIVE: To determine if midlife vascular risk factors are associated with late-life brain amyloid deposition, measured using florbetapir positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: The Atherosclerosis Risk in Communities (ARIC)-PET Amyloid Imaging Study, a prospective cohort study among 346 participants without dementia in 3 US communities (Washington County, Maryland; Forsyth County, North Carolina; and Jackson, Mississippi) who have been evaluated for vascular risk factors and markers since 1987-1989 with florbetapir PET scans in 2011-2013. Positron emission tomography image analysis was completed in 2015. EXPOSURES: Vascular risk factors at ARIC baseline (age 45-64 years; risk factors included body mass index ≥30, current smoking, hypertension, diabetes, and total cholesterol ≥200 mg/dL) were evaluated in multivariable models including age, sex, race, APOE genotype, and educational level. MAIN OUTCOMES AND MEASURES: Standardized uptake value ratios (SUVRs) were calculated from PET scans and a mean global cortical SUVR was calculated. Elevated florbetapir (defined as a SUVR >1.2) was the dependent variable. RESULTS: Among 322 participants without dementia and with nonmissing midlife vascular risk factors at baseline (mean age, 52 years; 58% female; 43% black), the SUVR (elevated in 164 [50.9%] participants) was measured more than 20 years later (median follow-up, 23.5 years; interquartile range, 23.0-24.3 years) when participants were between 67 and 88 (mean, 76) years old. Elevated body mass index in midlife was associated with elevated SUVR (odds ratio [OR], 2.06; 95% CI, 1.16-3.65). At baseline, 65 participants had no vascular risk factors, 123 had 1, and 134 had 2 or more; a higher number of midlife risk factors was associated with elevated amyloid SUVR at follow-up (30.8% [n = 20], 50.4% [n = 62], and 61.2% [n = 82], respectively). In adjusted models, compared with 0 midlife vascular risk factors, the OR for elevated SUVR associated with 1 vascular risk factor was 1.88 (95% CI, 0.95-3.72) and for 2 or more vascular risk factors was 2.88 (95% CI, 1.46-5.69). No significant race × risk factor interactions were found. Late-life vascular risk factors were not associated with late-life brain amyloid deposition (for ≥2 late-life vascular risk factors vs 0: OR, 1.66; 95% CI, 0.75-3.69). CONCLUSIONS AND RELEVANCE: An increasing number of midlife vascular risk factors was significantly associated with elevated amyloid SUVR; this association was not significant for late-life risk factors. These findings are consistent with a role of vascular disease in the development of Alzheimer disease.
Authors: Michael H Freitag; Rita Peila; Kamal Masaki; Helen Petrovitch; G Webster Ross; Lon R White; Lenore J Launer Journal: Stroke Date: 2005-12-08 Impact factor: 7.914
Authors: Jose Gutierrez; Lawrence Honig; Mitchell S V Elkind; Jay P Mohr; James Goldman; Andrew J Dwork; Susan Morgello; Randolph S Marshall Journal: Neurology Date: 2016-03-16 Impact factor: 9.910
Authors: Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky Journal: J Nucl Med Date: 2012-02-13 Impact factor: 10.057
Authors: Timothy J Hohman; Lauren R Samuels; Dandan Liu; Katherine A Gifford; Shubhabrata Mukherjee; Elleena M Benson; Ty Abel; Frederick L Ruberg; Angela L Jefferson Journal: Neurobiol Aging Date: 2015-06-06 Impact factor: 4.673
Authors: Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack Journal: Brain Date: 2015-01-15 Impact factor: 13.501
Authors: Andrea L C Schneider; Elizabeth Selvin; Menglu Liang; Lawrence Latour; L Christine Turtzo; Silvia Koton; Josef Coresh; Thomas Mosley; Christopher T Whitlow; Yun Zhou; Dean F Wong; Geoffrey Ling; Rebecca F Gottesman Journal: J Neurotrauma Date: 2019-05-23 Impact factor: 5.269
Authors: Nicole M Armstrong; Yang An; Luigi Ferrucci; Jennifer A Deal; Frank R Lin; Susan M Resnick Journal: J Gerontol A Biol Sci Med Sci Date: 2020-02-14 Impact factor: 6.053
Authors: Andreea M Rawlings; A Richey Sharrett; Marilyn S Albert; Josef Coresh; B Gwen Windham; Melinda C Power; David S Knopman; Keenan Walker; Sheila Burgard; Thomas H Mosley; Rebecca F Gottesman; Elizabeth Selvin Journal: Diabetes Care Date: 2019-05-21 Impact factor: 19.112
Authors: Keenan A Walker; B Gwen Windham; Charles H Brown; David S Knopman; Clifford R Jack; Thomas H Mosley; Elizabeth Selvin; Dean F Wong; Timothy M Hughes; Yun Zhou; Alden L Gross; Rebecca F Gottesman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Jennifer S Rabin; Aaron P Schultz; Trey Hedden; Anand Viswanathan; Gad A Marshall; Emily Kilpatrick; Hannah Klein; Rachel F Buckley; Hyun-Sik Yang; Michael Properzi; Vaishnavi Rao; Dylan R Kirn; Kathryn V Papp; Dorene M Rentz; Keith A Johnson; Reisa A Sperling; Jasmeer P Chhatwal Journal: JAMA Neurol Date: 2018-09-01 Impact factor: 18.302
Authors: Emily L Johnson; Gregory L Krauss; Alexandra K Lee; Andrea L C Schneider; Jennifer L Dearborn; Anna M Kucharska-Newton; Juebin Huang; Alvaro Alonso; Rebecca F Gottesman Journal: JAMA Neurol Date: 2018-11-01 Impact factor: 18.302
Authors: Jaimie C Hunter; Elizabeth P Handing; Ramon Casanova; Maragatha Kuchibhatla; Michael W Lutz; Santiago Saldana; Brenda L Plassman; Kathleen M Hayden Journal: Alzheimers Dement Date: 2018-02-01 Impact factor: 21.566
Authors: Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan Journal: Alzheimers Dement Date: 2019-08-01 Impact factor: 21.566